JP7317956B2 - 合成ペプチド、プロドラッグ、医薬組成物および使用 - Google Patents

合成ペプチド、プロドラッグ、医薬組成物および使用 Download PDF

Info

Publication number
JP7317956B2
JP7317956B2 JP2021522113A JP2021522113A JP7317956B2 JP 7317956 B2 JP7317956 B2 JP 7317956B2 JP 2021522113 A JP2021522113 A JP 2021522113A JP 2021522113 A JP2021522113 A JP 2021522113A JP 7317956 B2 JP7317956 B2 JP 7317956B2
Authority
JP
Japan
Prior art keywords
peptide
seq
ala
peptides
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530562A5 (https=
JP2021530562A (ja
JPWO2020006617A5 (https=
Inventor
カイオ・ヴィクトル・マシャード・フランサ・ド・ナシメント
ジエゴ・アロンソ・ホドリゲス・ドス・サントス・ダ・シウヴァ
ペルラ・ヴィラニ・ボルジェス・ダ・シウヴァ
マリア・エレナ・ジ・リマ・ペレス・ガルシア
カロリーナ・ヌーネス・ダ・シウヴァ
アドリアナ・モンテイロ・ジ・カストロ・ピメンタ
マルセラ・ヌネス・ジ・メロ・ブラガ
パウロ・グスタヴォ・サンパイオ・ラカティヴァ
アイロン・フランシスコ・ジ・パウラ・ジュニオール
ゲアハルト・マックス・グロス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biozeus Desenvolvimento De Produtos Biofarmaceuticos
Original Assignee
Biozeus Desenvolvimento De Produtos Biofarmaceuticos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biozeus Desenvolvimento De Produtos Biofarmaceuticos filed Critical Biozeus Desenvolvimento De Produtos Biofarmaceuticos
Publication of JP2021530562A publication Critical patent/JP2021530562A/ja
Publication of JP2021530562A5 publication Critical patent/JP2021530562A5/ja
Publication of JPWO2020006617A5 publication Critical patent/JPWO2020006617A5/ja
Application granted granted Critical
Publication of JP7317956B2 publication Critical patent/JP7317956B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2021522113A 2018-07-05 2019-07-04 合成ペプチド、プロドラッグ、医薬組成物および使用 Active JP7317956B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694162P 2018-07-05 2018-07-05
US62/694,162 2018-07-05
US16/502,215 US10905738B2 (en) 2018-07-05 2019-07-03 Synthetic peptides, prodrugs, pharmaceutical compositions and uses
US16/502,215 2019-07-03
PCT/BR2019/050249 WO2020006617A1 (en) 2018-07-05 2019-07-04 Synthetic peptides, prodrugs, pharmaceutical compositions and uses

Publications (4)

Publication Number Publication Date
JP2021530562A JP2021530562A (ja) 2021-11-11
JP2021530562A5 JP2021530562A5 (https=) 2022-06-24
JPWO2020006617A5 JPWO2020006617A5 (https=) 2022-06-24
JP7317956B2 true JP7317956B2 (ja) 2023-07-31

Family

ID=69059636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522113A Active JP7317956B2 (ja) 2018-07-05 2019-07-04 合成ペプチド、プロドラッグ、医薬組成物および使用

Country Status (8)

Country Link
US (1) US10905738B2 (https=)
EP (1) EP3818070B1 (https=)
JP (1) JP7317956B2 (https=)
KR (1) KR20210029161A (https=)
CN (1) CN112654634B (https=)
BR (1) BR112021000105A2 (https=)
CA (1) CA3104183A1 (https=)
WO (1) WO2020006617A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026507422A (ja) * 2023-02-17 2026-03-04 バイオゼウス バイオファーマシューティカル エス．エー． 性機能障害の治療のための局所用ペプチド製剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503823A (ja) 2002-08-27 2006-02-02 ウィリアム イー． シェル， 神経伝達物質の産生を推進および維持するための組成物および方法
JP2010504336A (ja) 2006-09-22 2010-02-12 オーソロジック コーポレイション 血管内皮機能不全を治療する方法
JP2015535808A (ja) 2012-08-20 2015-12-17 ウニベルシダーヂ フェデラル ヂ ミナス ジェライス−ウエフィエミジェー 合成ポリペプチドＰｎＴｘ（１９）、医薬組成物及びその使用
JP2016501851A (ja) 2012-11-20 2016-01-21 ノバルティス アーゲー 心不全治療用の合成鎖状アペリン模倣物
JP2016147905A (ja) 2007-01-19 2016-08-18 カイ ファーマシューティカルズ インコーポレーティッド ペプチド組成物の安定性および送達効率を上昇させるための修飾方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
AT387234B (de) 1987-03-05 1988-12-27 Vogelbusch Gmbh Vorrichtung zur zuechtung von dauerformen insbesondere filamentoeser mikroorganismen
US5470949A (en) 1992-12-15 1995-11-28 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for making amino acid glycosides and glycopeptides
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
CA2560956A1 (en) 2004-03-29 2005-10-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amphipathic glycopeptides
BRPI0800596A2 (pt) 2008-01-31 2009-09-22 Univ Minas Gerais método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
CN101585872A (zh) 2008-05-23 2009-11-25 成都蓉药集团四川长威制药有限公司 重组蛛毒蛋白、其制备方法和表达载体以及用于治疗ed的药物
KR20130139254A (ko) 2010-11-09 2013-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 피부 침투 및 세포 진입（ｓｐａｃｅ） 펩타이드 및 그의 사용방법
WO2015162195A1 (en) 2014-04-23 2015-10-29 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
WO2017068388A2 (pt) 2015-09-18 2017-04-27 Universidade Federal De Minas Gerais - Ufmg Uso do peptideo sintetico pntx-19 para tratamento de dor
KR101613302B1 (ko) 2015-12-30 2016-04-18 (주)넥스젠바이오텍 Sv82 폴리펩타이드 및 이를 유효성분으로 함유하는 피부 주름 개선 및 탄력 유지용 화장료 조성물
KR101636851B1 (ko) 2016-06-03 2016-07-06 (주)넥스젠바이오텍 피부 세포 증식 효과가 증가한 열 안정성 인간 상피세포성장인자-거미독 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선 및 탄력 유지용 화장료 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503823A (ja) 2002-08-27 2006-02-02 ウィリアム イー． シェル， 神経伝達物質の産生を推進および維持するための組成物および方法
JP2010504336A (ja) 2006-09-22 2010-02-12 オーソロジック コーポレイション 血管内皮機能不全を治療する方法
JP2016147905A (ja) 2007-01-19 2016-08-18 カイ ファーマシューティカルズ インコーポレーティッド ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
JP2015535808A (ja) 2012-08-20 2015-12-17 ウニベルシダーヂ フェデラル ヂ ミナス ジェライス−ウエフィエミジェー 合成ポリペプチドＰｎＴｘ（１９）、医薬組成物及びその使用
JP2016501851A (ja) 2012-11-20 2016-01-21 ノバルティス アーゲー 心不全治療用の合成鎖状アペリン模倣物

Also Published As

Publication number Publication date
WO2020006617A1 (en) 2020-01-09
US20200108118A1 (en) 2020-04-09
US10905738B2 (en) 2021-02-02
CA3104183A1 (en) 2020-01-09
CN112654634A (zh) 2021-04-13
JP2021530562A (ja) 2021-11-11
CN112654634B (zh) 2022-05-27
BR112021000105A2 (pt) 2021-03-30
KR20210029161A (ko) 2021-03-15
EP3818070A4 (en) 2022-03-16
EP3818070B1 (en) 2026-03-11
EP3818070A1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
US12285460B2 (en) Pharmaceutical compositions
ES3002666T3 (en) Improved peptide pharmaceuticals for treatment of nash and other disorders
JP6170019B2 (ja) α−メラニン形成細胞刺激ホルモンのペプチド類似体
US10471127B2 (en) Peptide pharmaceuticals for insulin resistance
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
KR101426070B1 (ko) Ｃｄ36 발현을 감소시키는 방법
KR20010072472A (ko) 혈뇌장벽 치료제
ES2632787T3 (es) Análogos agonistas del receptor opioide mu de las endomorfinas
ES2395546T3 (es) Antagonistas del receptor de bradicinina B1
BR112015011478B1 (pt) Produtos de peptídeo, seus usos e composição farmacêutica
US10624944B2 (en) Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (NASH)
ES3019509T3 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
JP7317956B2 (ja) 合成ペプチド、プロドラッグ、医薬組成物および使用
US20100004165A1 (en) Novel Protein Transduction Domains and Uses Therefor
HK40043121A (en) Synthetic peptides, prodrugs, pharmaceutical compositions and uses
HK40043121B (en) Synthetic peptides, prodrugs, pharmaceutical compositions and uses
CN105636975A (zh) 抗炎三肽
CA3238619A1 (en) Pharmaceutical compositions for the treatment of visceral pain
JPH09502175A (ja) 免疫およびｃｎｓ療法に有用な新規トリペプチド
US20060189536A1 (en) Treating the effects of nicotine
JP2009502976A (ja) 親水性ペプチド鎮痛薬の経口送達のためのペプチドコンジュゲート
JPH09510688A (ja) Ｃｘｃインタークリン分子のペプチド阻害剤
WO2019067887A1 (en) ENAC INHIBITOR PEPTIDES AND USES THEREOF
WO2006031976A2 (en) Compositions and methods for treating stat-6 associated diseases or conditions
NZ617824B2 (en) Improved peptide pharmaceuticals for insulin resistance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220616

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230719

R150 Certificate of patent or registration of utility model

Ref document number: 7317956

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150